HDFC ERGO General Insurance Company Limited



SER Clinical Trial Insurance - Proposal Form

The liability of the Company does not commence until the acceptance of the proposal has been formally intimated to the insured and full premium has been realized by the Company

												Spo	ons	or [Deta	ails																						
Sponsor Name]
Sponsor Address											_		_		_		_	_		_	_	_		_							_		4	_	4	_		_
Sponsor Type	Щ										_		_		_			_		_		_	_			"	Nobi	ile:		_			4	4	4	_		_
Ethical Committee								_			_		_		_		_	_				_					_				_		4		_			-
Address of Ethical Committee		<u> </u>									_							_		_		-		-									-	_	_			4
Address of Ethical Commutee	$\left - \right $	+						_		_	+	_	-		-		-	+	-	+		+				_	_	_	_		+		+	-	+	-		-
Conducting Company																																	1					
Conducting Company Address																											_						_	_				-
Conducting Company Address	-	_													_		_	_	_		_	-				_	_	_		_			+	+	_	_		-
Broker Name																				-		-											+	_	-			-
DIONEI INAILIE		+											-		-			+	-	+	-	+						-					+	+	+	-		٦
Country of Conduct		_																															_	_	_			7
Limit Per Trial (INR)																																	-		_			1
																		_			_	-											_	_	_			-
Limit Any One Person (INR)																																						_
[*] Please provide correct mobile number of the proposed insured, to receive information relating to policy servicing and premium acknowledgement.																																						
Please provide the following for each study																																						
tudy Protocol (Final Version) Synopsis of Study Patient Informed Consent Form																																						
Confidentially Statement The information you provide with this guestionnaire as well as all documents sent to us will be reviewed just for the purpose to estimate the risk involved and to provide insurance cover. Every information will be																																						
The information you provide with this questionnaire as well as all documents sent to us will be reviewed just for the purpose to estimate the risk involved and to provide insurance cover. Every information will be reated confidential and will not be disclosed to others without written authorization from Sponsor.																																						
Premium Details																																						
Amount Rs.																																						
Amount Rs. Rupees Sources of Fund																																						
Salary Business Other (Please Specify)																																						
Salary Business Other	Pleas	se op	becity)								Pe	mk	A a		+ F	Deta	ila																					
Name of the Bank Account Holder				1 1		-		1	ТТ	_	Da	INK.	AC	cou		Jeta	lis		1	1 1			1					1	1 1		-		T	-				1
Bank Account No.	+	+				+		1																				Δ		unt: \$	Savi	nas	\vdash	 1	(Curre	nt 🗌	Ì
Name of Bank	+	\square				-] 																	Br	anch							T	Ţ	\top			7
MICR Code (9 digit MICR code number of t	he ha	unk ar	nd hra	nch a	anne	arino	n on t	her	heau	le is	SUP	d by	the	hank									7		Die	anon		_				_	_	_				_
IFSC Code (11 character code appearing of															·)																							
I wish: Any refund due on the prem	ium p	ayme	ent/a	ny pa	ayme	nt/cl	aims	will	be di	rect	ly ci	redite	ed to	o my	afor	esaid	l Bai	nk Ac	cour	nt.*																		
*As per the IRDAI, its mandatory				• •	•																																	
Note: 1. Please provide a cancelled copy of chequ	ie of v	vourt	hanks		int																																	
 The Company will not be responsible in c Please ensure that you provide accurate 	ase of	f non	credi	t or d	lelay	in pi	roces	sing	g of p	ayoı	ut di	ue to	inc	ompl	ete/i	incor	recti	inforr	natic	on pr	ovide	ed by	the	cust	ome	r.												
										IN	รบ	RE	o's	DE	CL/	ARA	TIC	N																				ľ
I/we desire to effect SER Clinical Trial Insurance wi																																						
accurate representations. I/we agree that this applie with the terms and conditions prescribed by the Con-																																npany	/s p	olicy	for in	surar	ice alo	ng
I/we also agree that if any additions/alterations are associate partners to contact me via email, phone, General Insurance Company Limited for the purpos	SMS. I	I hereb	by grar	nt cons	sent t																																	
I/we understand the terms of cover of this insurance		•				e wou	ld be	effec	tive or	nly or	n ac	cepta	nce (of this	app	licatio	n by i	the Co	ompa	iny ar	id the	payr	nent	of the	prem	ium b	y me	e/us ir	n adv	ance.								
Place:																											Γ											7
Date:																																						
																																S	igna	ature	⇒ of t	ne P	ropos	er —

HDFC ERGO General Insurance Company Limited. IRDAI Reg. No. 146. CIN: U66030MH2007PLC177117. Registered & Corporate Office: 1st Floor, HDFC House, 165-166 Backbay Reclamation, H. T. Parekh Marg, Churchgate, Mumbai – 400 020. Customer Experience Management, Customer Happiness Center: D-301, 3rd Floor, Eastern Business District (Magnet Mall), LBS Marg, Bhandup (West), Mumbai – 400 078. For Claim/Policy related queries call us at +91 22 6234 6234/+91 120 6234 6234 or Visit Help Section on www.hdfcergo.com for policy copy/tax certificate/make changes/register & track claim. Trade Logo displayed above belongs to HDFC Bank Ltd and ERGO International AG and used by the Company under license. UIN: SER Clinical Trial Insurance - IRDAN125CP0047V01200910.

LIABILITY OF THE COMPANY DOES NOT COMMENCE UNTIL THE PROPOSAL HAS BEEN ACCEPTED AND THE PREMIUM HAS BEEN RECEIVED IN ACCORDANCE WITH THE PROVISIONS OF SECTION 64VB OF THE INSURANCE ACT, 1938

NOTICE TO APPLICANT - PLEASE READ CAREFULLY.

ANY PERSON WHO, BY ANY STATEMENT, PROMISE OR REPRESENTATION WHICH HE KNOWS TO BE FALSE, MISLEADING OR DECEPTIVE, OR BY ANY DISHONEST CONCEALMENT OF MATERIAL FACTS, OR BY THE RECKLESS MAKING (DISHONEST OR OTHERWISE) OF ANY STATEMENT, PROMISE OR REPRESENTATION WHICH IS FALSE, MISLEADING OR DECEPTIVE, INDUCES OR ATTEMPTS TO INDUCE ANOTHER PERSON TO ENTER INTO OR OFFER TO ENTER INTO ANY CONTRACT OF INSURANCE COMMITS AN OFFENCE.

Notice

The rebate of premiums shall be allowed only in accordance with the details given in the prospectus or table of premium rates [or, as the case may be, the relevant document]. An offer or acceptance of any other rebate shall be an offence under section 41 of the Act.

Section 41 of the Insurance Act: Prohibition of Rebates

- 1) No person shall allow or offer to allow, either directly or indirectly, as an inducement to any person to take out or renew or continue an insurance in respect of any kind of risk relating to lives or property in India, any rebate of the whole or part of the commission payable or any rebate of the premium shown on the policy, nor shall any person taking out or renewing or continuing a policy accept any rebate, except such rebate as may be allowed in accordance with the published prospectuses or tables of the Insurer.
- 2) Any person making default in complying with the provisions of this section shall be punishable with fine which may extend to ₹10 Lakhs.

							Clin	nical	Tria	al No) .										
Title of Study																					
Internal Number/ Study Code																			Ť		
Number of Research Subjects																			Ť		
Start Date of Study																			-		
End Date of Study	-	<u> </u>		<u> </u>	<u> </u>					<u> </u>									Ť	-	
Duration of Study																			T		
Phase																			Ť		
Period Research Subject Under Drug		<u> </u>		<u> </u>	<u> </u>					<u> </u>						<u> </u>	<u> </u>		Ť	1	
API used in the study if any																			Ť		
Test of Medical Devices																			T		
Invasive Surgery		Ť		<u> </u>	<u> </u>					<u> </u>						<u> </u>	<u> </u>		Ť	1	
Xenotransplantation during trial																			Ť		
Risk arising out of the trial																			Ť		
Cover required from																					